Angiogenesis: What can it offer for future medicine?

Experimental Cell Research

Volumn 316, Issue 8, 2010, Pages 1304-1308

  Cao, Yihai ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiogenesis; Cancer; Cardiovascular disease; Ocular disease; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE MODEL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG TARGETING; EYE DISEASE; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OBESITY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; THROMBOSIS; ANIMAL; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77952577457     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.02.031     Document Type: Review

References (46)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
2. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351:2805-2816.
3. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
4. Cao Y. Monotherapy versus combination therapy of angiogenic and arteriogenic factors for the treatment of ischemic disorders. Curr. Mol. Med. 2009, 9:967-972.
5. Simons M. Angiogenesis: where do we stand now?. Circulation 2005, 111:1556-1566.
6. Cao R., Brakenhielm E., Pawliuk R., Wariaro D., Post M.J., Wahlberg E., Leboulch P., Cao Y. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 2003, 9:604-613.
7. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
8. Garassino M.C., Hollander L., Torri V. Bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2007, 356:1373. (author reply 1374-5).
9. Haines I.E., Miklos G.L. Paclitaxel plus bevacizumab for metastatic breast cancer. N. Engl. J. Med. 2008, 358:1637. (author reply 1637-8).
10. Plotkin S.R., Stemmer-Rachamimov A.O., Barker F.G., Halpin C., Padera T.P., Tyrrell A., Sorensen A.G., Jain R.K., di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 2009, 361:358-367.
11. Atkins M., Jones C.A., Kirkpatrick P. Sunitinib maleate. Nat. Rev. Drug Discov. 2006, 5:279-280.
12. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5:835-844.
13. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N. Engl. J. Med. 2007, 356:185-187.
14. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R.M. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356:125-134.
15. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356:115-124.
16. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.L., Verslype C., Scheithauer W., Shang A., Cosaert J., Moore M.J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27:2231-2237.
17. Burger R.A. Experience with bevacizumab in the management of epithelial ovarian cancer. J. Clin. Oncol. 2007, 25:2902-2908.
18. Kaye S.B. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?. J. Clin. Oncol. 2007, 25:5150-5152.
19. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358:2039-2049.
20. Jain R.K., Duda D.G., Willett C.G., Sahani D.V., Zhu A.X., Loeffler J.S., Batchelor T.T., Sorensen A.G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009, 6:327-338.
21. Cao Y., Zhong W., Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin. Cancer Biol. 2009, 19:338-343.
22. Cao Y. Antiangiogenic cancer therapy. Semin. Cancer Biol. 2004, 14:139-145.
23. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286.
24. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17069-17074.
25. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., Shalinsky D.R., Hu-Lowe D.D., McDonald D.M. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
26. Cao Y. Angiogenesis and lymphangiogenesis in common diseases. Curr. Mol. Med. 2009, 9:928. Editorial.
27. Cao R., Jensen L.D., Soll I., Hauptmann G., Cao Y. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One 2008, 3:e2748.
28. Dahl Ejby L. Jensen, R. Cao, E. M. Hedlund, I. Soll, J. O. Lundberg, G. Hauptmann, J. F. Steffensen and Y. Cao, Nitric oxide permits hypoxia-induced lymphatic perfusion by controlling arterial-lymphatic conduits in zebrafish and glass catfish. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18408-18413.
29. Lee S.L., Rouhi P., Dahl Jensen L., Zhang D., Ji H., Hauptmann G., Ingham P., Cao Y. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19485-19490.
30. Lendahl U., Lee K.L., Yang H., Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nat. Rev. Genet. 2009, 10:821-832.
31. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., Cao Y., Berkenstam A., Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001, 414:550-554.
32. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
33. Stone E.M. A very effective treatment for neovascular macular degeneration. N. Engl. J. Med. 2006, 355:1493-1495.
34. Liew G., Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2007, 356:747-748. (author reply 749-50).
35. http://www.nei.nih.gov/health/maculardegen/armd_facts.asp, pp.
36. Rodriguez-Fontal M., Alfaro V., Kerrison J.B., Jablon E.P. Ranibizumab for diabetic retinopathy. Curr. Diabetes Rev. 2009, 5:47-51.
37. Cao Y. Angiogenesis modulates adipogenesis and obesity. J. Clin. Invest. 2007, 117:2362-2368.
38. Brakenhielm E., Cao R., Gao B., Angelin B., Cannon B., Parini P., Cao Y. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ. Res. 2004, 94:1579-1588.
39. Rupnick M.A., Panigrahy D., Zhang C.Y., Dallabrida S.M., Lowell B.B., Langer R., Folkman M.J. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10730-10735.
40. Kahn C.R. Medicine. Can we nip obesity in its vascular bud?. Science 2008, 322:542-543.
41. Xue Y., Cao R., Nilsson D., Chen S., Westergren R., Hedlund E.M., Martijn C., Rondahl L., Krauli P., Walum E., Enerback S., Cao Y. FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10167-10172.
42. Xue Y., Petrovic N., Cao R., Larsson O., Lim S., Chen S., Feldmann H.M., Liang Z., Zhu Z., Nedergaard J., Cannon B., Cao Y. Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. Cell Metab. 2009, 9:99-109.
43. Lu H., Xu X., Zhang M., Cao R., Brakenhielm E., Li C., Lin H., Yao G., Sun H., Qi L., Tang M., Dai H., Zhang Y., Su R., Bi Y., Cao Y. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12140-12145.
44. Cao Y., Hong A., Schulten H., Post M.J. Update on therapeutic neovascularization. Cardiovasc. Res. 2005, 65:639-648.
45. Zhang J., Cao R., Zhang Y., Jia T., Cao Y., Wahlberg E. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J. 2009, 23:153-163.
46. Cao Y., Langer R. Optimizing the delivery of cancer drugs that block angiogenesis. Sci. Transl. Med. 2010, 15:ps3.